Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27553947 | 0.74 | CRBN (0.49) | CRBNDDB1 | |
| SCHEMBL6696686 | 0.70 | CRBN (0.47) | CRBNDDB1 | |
| SCHEMBL9909362 | 0.67 | HPGD (0.56) | HPGDCYP3A4CYP2C19RAB9APOLB | |
| SCHEMBL1894982 | 0.67 | HPGD (0.56) | HPGDCYP3A4CYP2C19RAB9APOLB | |
| SCHEMBL28115672 | 0.65 | ALDH1A1 (0.51) | HPGDCYP3A4CYP2C19RAB9APOLB | |
| SCHEMBL20805296 | 0.65 | CRBN (0.52) | CRBNDDB1HTTGAAPOLB | |
| SCHEMBL28421777 | 0.65 | CRBN (0.61) | CRBNDDB1 | |
| SCHEMBL5370802 | 0.64 | HPGD (0.57) | HPGDCYP3A4CYP2C19RAB9APOLB | |
| SCHEMBL6695893 | 0.64 | CRBN (0.50) | CRBNDDB1HTTGAAPOLB | |
| SCHEMBL5468924 | 0.64 | KCNA5 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048859-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GRUENENTHAL GMBH (DE) | 2004-03-11 | — | — | US | disclosed |
| US-6656937-B2 | Immunology moderators; interleukin antagonist; anticancer agents | GRUENENTHAL, GMBH (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20030064987-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GRUENENTHAL GMBH | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048859-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GCDH, IL4I1, IL2 | CRBN 949/4885DDB1 2435/4885HTT 3253/4885 |
| US-20030064987-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GCDH, IL4I1, IL2 | CRBN 949/4885DDB1 2435/4885HTT 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.